Corona Remedies Management Guidance Tracker

8 forward-looking guidance items tracked across 2 quarters.

Growth

Q2 FY2615% revenue CAGR and 20% PAT/EPS growth for next 3-4 yearsTracked

Management targets 15% revenue CAGR and 20% PAT or EPS growth over the next 3-4 years, underpinned by organic growth, brand acquisitions, and new therapy entries.

Q4 FY2625% revenue growth on acquired brandsActive

Acquired brands (Wokadin, Bayer portfolio) are expected to grow at 25% in FY27.

Expansion

Q2 FY26New hormonal plant commercial production by Q2 FY27Tracked

The new hormonal plant at Ahmedabad will kickstart commercial production by end of Q2 or early Q3 of FY27, with WHO-GMP expected by Q4 FY27 and EU-GMP by FY27-end.

Revenue

Q2 FY26International business contribution to reach 8-9% in a couple of yearsTracked

International business, currently ~3.5% of revenue, is expected to grow to 8-9% in a couple of years, driven by hormonal product exports to Europe, UK, Australia, and other regions.

Q4 FY2615% organic revenue growth in FY27Active

Management expects to sustain 15%+ revenue growth organically for FY27.

Other

Q2 FY26R&D spend to remain below 2% of revenueActive

R&D expenditure will stay below 2% of revenue as the company scales, with ~100 scientists currently; no major increase planned.

Margins

Q4 FY2620%+ PAT growth in FY27Active

Management guided for 20%+ PAT growth in FY27.

Capex

Q4 FY26Hormone plant operational in Q1/Q2 FY27Active

The dedicated hormone manufacturing plant is expected to become operational in Q1 or Q2 of FY27.